What kind of side effects can patients expect from Polivy?
Polivy, also known as polatuzumab vedotin, is a monoclonal antibody-drug conjugate used in the treatment of certain types of non-Hodgkin's lymphoma [1]. While the exact frequency and severity of side effects can vary from person to person, Polivy's label highlights several common adverse reactions [2].
Common side effects of Polivy:
According to the drug's label, the most common side effects (≥20%) include:
* Nausea
* Decreased white blood cell count (neutropenia)
* Infection
* Fatigue
* Diarrhea
* Vomiting
* Decreased platelet count (thrombocytopenia)
* Decreased red blood cell count (anemia)
* Peripheral neuropathy (nerve damage or pain)
Less common side effects:
Other side effects reported in 1-20% of patients include:
* Rash
* Itching
* Cough
* Weight loss
* Abdominal pain
* Bacterial or viral infections
* Infusion site reactions
Rare but serious side effects:
Polivy can also cause more severe side effects in a small percentage of patients, including:
* Hemorrhage (excessive bleeding)
* Cytopenias (low blood cell counts)
* Infusion-related reactions (IRRs)
* Neurotoxicity (nerve damage)
Important consideration for patients:
It's essential for patients to discuss the potential risks and benefits of Polivy with their healthcare provider, as the likelihood and severity of side effects can vary depending on individual factors, such as age, overall health, and previous treatments [3].
Clinical trial data:
Clinical trials have provided valuable insights into Polivy's side effect profile. A Phase 1-2 study conducted by Roche, the manufacturer of Polivy, reported that the most common adverse reactions (≥20%) were neutropenia, infection, fatigue, diarrhea, nausea, and vomiting [4].
What you should know:
While Polivy's side effects can be significant, it's essential to note that many patients can tolerate the drug with proper management. Your healthcare provider can help you weigh the benefits and risks of Polivy and make informed decisions about your treatment plan.
References:
[1] FDA. (2020). Polivy.
[2] Roche. (2020). Polivy Prescribing Information.
[3] FDA. (2020). FDA Approves Polivy for Certain Types of Non-Hodgkin's Lymphoma.
[4] Advani, R. et al. (2018). Phase 1-2 study of polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma. Blood Cancer Journal, 8(10), 1018.
DrugPatentWatch.com
For more information on Polivy's patent status and exclusivity, please visit DrugPatentWatch.com www.drugpatentwatch.com.